Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 1/2020

01-02-2020 | Respiratory Microbiota

Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis

Authors: Weihua Chen, Yiran Wei, Aizhen Xiong, Yanmei Li, Huida Guan, Qixia Wang, Qi Miao, Zhaolian Bian, Xiao Xiao, Min Lian, Jun Zhang, Bo Li, Qin Cao, Zhuping Fan, Weici Zhang, Dekai Qiu, Jingyuan Fang, M. Eric Gershwin, Li Yang, Ruqi Tang, Xiong Ma

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2020

Login to get access

Abstract

Accumulation of bile acids (BAs) contributes significantly to the pathogenesis of primary biliary cholangitis (PBC). Here, we sought to systematically characterize the serum and fecal BA profiles and the linkage between BAs and gut microbiota in PBC. The serum and fecal BAs were compared between 65 UDCA treatment-naive PBC and 109 healthy controls using UPLC-MS in cross-sectional study. In a prospective study, a subgroup of patients was enrolled for BA and microbiota analysis before and after UDCA therapy. BA compositions in serum and feces significantly differed between treatment-naive PBC and controls. Particularly, PBC was associated with decreased conversions of conjugated to unconjugated, and primary to secondary BAs, indicating impaired microbial metabolism of BAs. PBC patients at advanced stage exhibited a more abnormal BA profile compared with early-stage patients. UDCA treatment led to a decreased level of taurine-conjugated BAs, thereby reversing the conjugated/unconjugated ratio in PBC. Moreover, the level of secondary BAs such as DCA and conjugated DCA inversely correlated with PBC-enriched gut microbes (e.g., Veillonella, Klebsiella), while positively correlated with control-enriched microbes (e.g., Faecalibacterium, Oscillospira). Microbiota analysis also revealed a significant increase of taurine-metabolizing bacteria Bilophila spp. in patients after UDCA, which was strongly correlated with decreased taurine-conjugated BAs. In addition, serum FGF19 was remarkably increased in treatment-naïve PBC and decreased after UDCA. Our study established specific alterations of BA compositions in serum and feces of PBC, suggesting the potential for using BAs for diagnosis, and highlighting the possibility of modulating BA profile by altering gut microbiota.
Appendix
Available only for authorised users
Literature
2.
go back to reference Gerussi A, Cristoferi L, Carbone M et al (2018) The immunobiology of female predominance in primary biliary cholangitis. J Autoimmun 95:124–132PubMedCrossRef Gerussi A, Cristoferi L, Carbone M et al (2018) The immunobiology of female predominance in primary biliary cholangitis. J Autoimmun 95:124–132PubMedCrossRef
3.
go back to reference Rojas M, Restrepo-Jimenez P, Monsalve DM et al (2018) Molecular mimicry and autoimmunity. J Autoimmun 95:100–123PubMedCrossRef Rojas M, Restrepo-Jimenez P, Monsalve DM et al (2018) Molecular mimicry and autoimmunity. J Autoimmun 95:100–123PubMedCrossRef
4.
go back to reference Jansen PL, Ghallab A, Vartak N et al (2017) The ascending pathophysiology of cholestatic liver disease. Hepatology. 65:722–738PubMedCrossRef Jansen PL, Ghallab A, Vartak N et al (2017) The ascending pathophysiology of cholestatic liver disease. Hepatology. 65:722–738PubMedCrossRef
5.
go back to reference Fickert P, Wagner M (2017) Biliary bile acids in hepatobiliary injury—what is the link? J Hepatol 67:619–631PubMedCrossRef Fickert P, Wagner M (2017) Biliary bile acids in hepatobiliary injury—what is the link? J Hepatol 67:619–631PubMedCrossRef
6.
go back to reference Li M, Cai SY, Boyer JL (2017) Mechanisms of bile acid mediated inflammation in the liver. Mol Asp Med 56:45–53CrossRef Li M, Cai SY, Boyer JL (2017) Mechanisms of bile acid mediated inflammation in the liver. Mol Asp Med 56:45–53CrossRef
7.
go back to reference Corpechot C (2012) Primary biliary cirrhosis and bile acids. Clin Res Hepatol Gastroenterol 36(Suppl 1):S13–S20PubMedCrossRef Corpechot C (2012) Primary biliary cirrhosis and bile acids. Clin Res Hepatol Gastroenterol 36(Suppl 1):S13–S20PubMedCrossRef
8.
go back to reference Hohenester S, Wenniger LM, Paulusma CC et al (2012) A biliary HCO3− umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology. 55:173–183PubMedCrossRef Hohenester S, Wenniger LM, Paulusma CC et al (2012) A biliary HCO3 umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology. 55:173–183PubMedCrossRef
9.
go back to reference Wang Y, Aoki H, Yang J et al (2017) The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice. Hepatology. 65:2005–2018PubMedCrossRef Wang Y, Aoki H, Yang J et al (2017) The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice. Hepatology. 65:2005–2018PubMedCrossRef
10.
go back to reference Russell DW (2003) The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72:137–174PubMedCrossRef Russell DW (2003) The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72:137–174PubMedCrossRef
11.
go back to reference Lu TT, Makishima M, Repa JJ et al (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 6:507–515PubMedCrossRef Lu TT, Makishima M, Repa JJ et al (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 6:507–515PubMedCrossRef
12.
go back to reference Inagaki T, Choi M, Moschetta A et al (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217–225PubMedCrossRef Inagaki T, Choi M, Moschetta A et al (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217–225PubMedCrossRef
13.
go back to reference Holt JA, Luo G, Billin AN et al (2003) Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17:1581–1591PubMedPubMedCentralCrossRef Holt JA, Luo G, Billin AN et al (2003) Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17:1581–1591PubMedPubMedCentralCrossRef
14.
go back to reference Chascsa D, Carey EJ, Lindor KD (2017) Old and new treatments for primary biliary cholangitis. Liver Int 37:490–499PubMedCrossRef Chascsa D, Carey EJ, Lindor KD (2017) Old and new treatments for primary biliary cholangitis. Liver Int 37:490–499PubMedCrossRef
15.
go back to reference Nevens F, Andreone P, Mazzella G et al (2016) A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 375:631–643CrossRefPubMed Nevens F, Andreone P, Mazzella G et al (2016) A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 375:631–643CrossRefPubMed
16.
go back to reference Kowdley KV, Luketic V, Chapman R et al (2018) A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology. 67:1890–1902PubMedCrossRef Kowdley KV, Luketic V, Chapman R et al (2018) A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology. 67:1890–1902PubMedCrossRef
17.
go back to reference Li Y, Tang R, Leung PSC et al (2017) Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev 16:885–896PubMedCrossRef Li Y, Tang R, Leung PSC et al (2017) Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev 16:885–896PubMedCrossRef
18.
go back to reference Molinaro A, Wahlstrom A, Marschall HU (2018) Role of bile acids in metabolic control. Trends Endocrinol Metab 29:31–41PubMedCrossRef Molinaro A, Wahlstrom A, Marschall HU (2018) Role of bile acids in metabolic control. Trends Endocrinol Metab 29:31–41PubMedCrossRef
19.
go back to reference Wahlstrom A, Sayin SI, Marschall HU et al (2016) Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab 24:41–50PubMedCrossRef Wahlstrom A, Sayin SI, Marschall HU et al (2016) Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab 24:41–50PubMedCrossRef
20.
go back to reference Trauner M, Fuchs CD, Halilbasic E et al (2017) New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Hepatology. 65:1393–1404PubMedCrossRef Trauner M, Fuchs CD, Halilbasic E et al (2017) New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Hepatology. 65:1393–1404PubMedCrossRef
22.
go back to reference Dilger K, Hohenester S, Winkler-Budenhofer U et al (2012) Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol 57:133–140PubMedCrossRef Dilger K, Hohenester S, Winkler-Budenhofer U et al (2012) Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol 57:133–140PubMedCrossRef
23.
go back to reference Trottier J, Bialek A, Caron P et al (2012) Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Dig Liver Dis 44:303–310PubMedCrossRef Trottier J, Bialek A, Caron P et al (2012) Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Dig Liver Dis 44:303–310PubMedCrossRef
24.
go back to reference Bell LN, Wulff J, Comerford M et al (2015) Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis. Liver Int 35:263–274PubMedCrossRef Bell LN, Wulff J, Comerford M et al (2015) Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis. Liver Int 35:263–274PubMedCrossRef
25.
go back to reference Tang YM, Wang JP, Bao WM et al (2015) Urine and serum metabolomic profiling reveals that bile acids and carnitine may be potential biomarkers of primary biliary cirrhosis. Int J Mol Med 36:377–385PubMedPubMedCentralCrossRef Tang YM, Wang JP, Bao WM et al (2015) Urine and serum metabolomic profiling reveals that bile acids and carnitine may be potential biomarkers of primary biliary cirrhosis. Int J Mol Med 36:377–385PubMedPubMedCentralCrossRef
26.
go back to reference Lv LX, Fang DQ, Shi D et al (2016) Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. Environ Microbiol 18:2272–2286PubMedCrossRef Lv LX, Fang DQ, Shi D et al (2016) Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. Environ Microbiol 18:2272–2286PubMedCrossRef
27.
go back to reference Li Z, Lin B, Lin G et al (2017) Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS One 12:e0178580PubMedPubMedCentralCrossRef Li Z, Lin B, Lin G et al (2017) Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS One 12:e0178580PubMedPubMedCentralCrossRef
28.
go back to reference Tang R, Wei Y, Li Y et al (2018) Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut. 67:534–541PubMedCrossRef Tang R, Wei Y, Li Y et al (2018) Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut. 67:534–541PubMedCrossRef
29.
30.
go back to reference Chazouilleres O, Wendum D, Serfaty L et al (1998) Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 28:296–301PubMedCrossRef Chazouilleres O, Wendum D, Serfaty L et al (1998) Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 28:296–301PubMedCrossRef
31.
go back to reference Corpechot C, Chazouilleres O, Poupon R (2011) Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 55:1361–1367PubMedCrossRef Corpechot C, Chazouilleres O, Poupon R (2011) Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 55:1361–1367PubMedCrossRef
32.
go back to reference Zhang LN, Shi TY, Shi XH et al (2013) Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology. 58:264–272PubMedCrossRef Zhang LN, Shi TY, Shi XH et al (2013) Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology. 58:264–272PubMedCrossRef
33.
go back to reference Yang L, Xiong A, He Y et al (2008) Bile acids metabonomic study on the CCl4- and alpha-naphthylisothiocyanate-induced animal models: quantitative analysis of 22 bile acids by ultraperformance liquid chromatography-mass spectrometry. Chem Res Toxicol 21:2280–2288PubMedCrossRef Yang L, Xiong A, He Y et al (2008) Bile acids metabonomic study on the CCl4- and alpha-naphthylisothiocyanate-induced animal models: quantitative analysis of 22 bile acids by ultraperformance liquid chromatography-mass spectrometry. Chem Res Toxicol 21:2280–2288PubMedCrossRef
36.
go back to reference McCoy KD, Ronchi F, Geuking MB (2017) Host-microbiota interactions and adaptive immunity. Immunol Rev 279:63–69PubMedCrossRef McCoy KD, Ronchi F, Geuking MB (2017) Host-microbiota interactions and adaptive immunity. Immunol Rev 279:63–69PubMedCrossRef
37.
go back to reference Macpherson AJ, Koller Y, McCoy KD (2015) The bilateral responsiveness between intestinal microbes and IgA. Trends Immunol 36:460–470PubMedCrossRef Macpherson AJ, Koller Y, McCoy KD (2015) The bilateral responsiveness between intestinal microbes and IgA. Trends Immunol 36:460–470PubMedCrossRef
38.
go back to reference ter Borg PC, Schalm SW, Hansen BE et al (2006) Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 101:2044–2050CrossRefPubMed ter Borg PC, Schalm SW, Hansen BE et al (2006) Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 101:2044–2050CrossRefPubMed
39.
40.
go back to reference Joyce SA, Gahan CG (2016) Bile acid modifications at the microbe-host interface: potential for nutraceutical and pharmaceutical interventions in host health. Annu Rev Food Sci Technol 7:313–333PubMedCrossRef Joyce SA, Gahan CG (2016) Bile acid modifications at the microbe-host interface: potential for nutraceutical and pharmaceutical interventions in host health. Annu Rev Food Sci Technol 7:313–333PubMedCrossRef
41.
go back to reference Jones BV, Begley M, Hill C et al (2008) Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A 105:13580–13585PubMedPubMedCentralCrossRef Jones BV, Begley M, Hill C et al (2008) Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A 105:13580–13585PubMedPubMedCentralCrossRef
42.
go back to reference Inagaki T, Moschetta A, Lee YK et al (2006) Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 103:3920–3925PubMedPubMedCentralCrossRef Inagaki T, Moschetta A, Lee YK et al (2006) Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 103:3920–3925PubMedPubMedCentralCrossRef
43.
go back to reference Ridlon JM, Kang DJ, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47:241–259PubMedCrossRef Ridlon JM, Kang DJ, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47:241–259PubMedCrossRef
44.
45.
go back to reference Tabibian JH, O'Hara SP, Trussoni CE et al (2016) Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology. 63:185–196PubMedCrossRef Tabibian JH, O'Hara SP, Trussoni CE et al (2016) Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology. 63:185–196PubMedCrossRef
46.
go back to reference Devkota S, Wang Y, Musch MW et al (2012) Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10−/− mice. Nature. 487:104–108PubMedPubMedCentralCrossRef Devkota S, Wang Y, Musch MW et al (2012) Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10−/− mice. Nature. 487:104–108PubMedPubMedCentralCrossRef
47.
go back to reference Wewalka M, Patti ME, Barbato C et al (2014) Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin. J Clin Endocrinol Metab 99:1442–1451PubMedPubMedCentralCrossRef Wewalka M, Patti ME, Barbato C et al (2014) Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin. J Clin Endocrinol Metab 99:1442–1451PubMedPubMedCentralCrossRef
48.
go back to reference Schaap FG, van der Gaag NA, Gouma DJ et al (2009) High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology. 49:1228–1235PubMedCrossRef Schaap FG, van der Gaag NA, Gouma DJ et al (2009) High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology. 49:1228–1235PubMedCrossRef
49.
go back to reference Wunsch E, Milkiewicz M, Wasik U et al (2015) Expression of hepatic fibroblast growth factor 19 is enhanced in primary biliary cirrhosis and correlates with severity of the disease. Sci Rep 5:13462PubMedPubMedCentralCrossRef Wunsch E, Milkiewicz M, Wasik U et al (2015) Expression of hepatic fibroblast growth factor 19 is enhanced in primary biliary cirrhosis and correlates with severity of the disease. Sci Rep 5:13462PubMedPubMedCentralCrossRef
50.
go back to reference Mueller M, Thorell A, Claudel T et al (2015) Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol 62:1398–1404PubMedPubMedCentralCrossRef Mueller M, Thorell A, Claudel T et al (2015) Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol 62:1398–1404PubMedPubMedCentralCrossRef
Metadata
Title
Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis
Authors
Weihua Chen
Yiran Wei
Aizhen Xiong
Yanmei Li
Huida Guan
Qixia Wang
Qi Miao
Zhaolian Bian
Xiao Xiao
Min Lian
Jun Zhang
Bo Li
Qin Cao
Zhuping Fan
Weici Zhang
Dekai Qiu
Jingyuan Fang
M. Eric Gershwin
Li Yang
Ruqi Tang
Xiong Ma
Publication date
01-02-2020
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 1/2020
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-019-08731-2

Other articles of this Issue 1/2020

Clinical Reviews in Allergy & Immunology 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.